Ramipril formulation

• US 20070053975A1
• Filed: 08/24/2006
• Published: 03/08/2007
• Est. Priority Date: 09/06/2005
• Status: Abandoned Application

• Current Assignee: Selamine Limited (Abbvie Incorporated)
• Original Assignee: Selamine Limited (Abbvie Incorporated)
• Inventors: Harrison, Paul, Power, Anna
• Application Number:
  US11/509,032
• Publication Number:
  US 20070053975A1
• Time in Patent Office: Days
• US Class Current: 424/464
• CPC Class Codes: A61K 31/403 condensed with carbocyclic rings, e.g. carbazole
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• CPC Class Codes: A61K 9/2009 Inorganic compounds
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

A Ramipril formulation rapidly disintegrates after ingestion and exhibits substantially no food effect.

Claims

1. A Ramipril formulation which disintegrates in less than 15 minutes in the USP disintegration test carried out over the anticipated viscosity range in the stomach and which disintegrates in less than 3 minutes in water in the USP disintegration test.

2. The formulation of claim 1, wherein at least 90% of the Ramipril is dissolved within 10 minutes of administration measured using the USP method, using 0.1NHCL, 50 rpm paddles in 500 ml.

9. The formulation of claim 1 comprising a disintegrant.

10. The formulation of claim 9 wherein the disintegrant is selected from croscarmellose cellulose, crospovidone and sodium starch glycollate.

12. A method for treating or preventing a disease in a mammal selected from the group consisting of hypertension, heart failure, stroke, myocardial infarction, diabetes and cardiovascular disease or for reducing the risk of further strokes, heart attacks and cognitive impairment among stroke patients comprising administering to a mammal in need of such treatment, the formulation of claim 1.

13. The method of claim 12, wherein the mammal has eaten.

15. The kit of claim 14, wherein the oral dosage form is a formulation according to claim 1.

3. A Ramipril containing formulation giving dissolution of Ramipril in vivo which is sufficiently rapid that presence or absence of food in the gastrointestinal tract does not substantially alter absorption of the Ramipril.

4. The Ramipril containing formulation of claim 3, wherein peak plasma concentration of Ramipril in fed patients is not less than a third that in fasted patients.

5. The Ramipril containing formulation of claim 3, wherein peak plasma concentration of Ramipril in fed patients is not less than a half that in fasted patients.

6. The Ramipril containing formulation of claim 3, wherein median time to maximum plasma concentration in fed patients is not increased by more than 4 fold in fasted patients.

7. The Ramipril containing formulation of claim 3, wherein median time to maximum plasma concentration in fed patients is not increased by more than 2 fold in fasted patients.

8. An oral Ramipril formulation which does not exhibit a food effect.

11. A Ramipril formulation which disintegrates in less than 3 minutes in a model for high agitation in a fasted state, in less than 15 minutes in a model for high agitation in a fed state, and in less than 30 minutes in a model for low agitation in a fed state.

14. A kit, comprising

a container,

an oral dosage form of Ramipril that does not exhibit a food effect, and

written matter non-limited as to whether the dosage form can be taken with or without food.